Ignite Creation Date:
2024-05-06 @ 7:51 AM
Last Modification Date:
2024-10-26 @ 11:53 AM
Study NCT ID:
NCT02617550
Status:
COMPLETED
Last Update Posted:
2021-12-29
First Post:
2015-11-11
Brief Title:
Vericiguat Drug-drug Interaction With Nitroglycerin in Stable Coronary Artery Disease Patients
Sponsor:
Bayer
Organization:
Bayer
Study Overview
Official Title:
Evaluation of the Effect of 04 mg Nitroglycerin Spray After Pretreatment With Multiple Once Daily Oral Doses of 25 mg 5 mg and 10 mg Vericiguat BAY 1021189 Each Given Over 14 3 Days on Safety Tolerability and Blood Pressure in a Multi-center Randomized Placebo-controlled Double-blind Group Comparison Study in Stable Coronary Artery Disease CAD Patients Aged 30 to 80 Years
Status:
COMPLETED
Status Verified Date:
2021-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
VENICE
Brief Summary:
This study is intended to investigate the effect of nitroglycerin on vericiguat in patients with stable coronary artery disease CAD Nitroglycerin is the standard therapy to treat acute crisis of angina Thus there is a high likelihood of co-administration of both drugs in the target indication of vericiguat worsening heart failure HF Therefore it is important to investigate the safety and tolerability of vericiguat and nitroglycerin which may be used as unprescribed on-demand treatment by patients with acute episodes of angina pectoris
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2015-001444-11 | EUDRACT_NUMBER | None | None |